Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement
Truist has reiterated its Buy rating on Insulet Corporation (PODD) following the company’s announcement of a global field safety correction for its Omnipod 5 Automated Insulin Delivery System. The correction addresses a software issue that could lead to over-delivery of insulin, but Truist believes the impact on Insulet’s financials, new patient starts, and market share loss will be minimal given the low historical incidence rate of the flaw and the company’s proactive communication.